Stock Movers: Alphabet, Caterpillar, Eli Lilly (Podcast)

Alphabet shares fell more than 13% after third-quarter sales of $111.2 billion missed projections and search and other-channel ad sales grew at their slowest pace in five quarters; its future resource commitments totaled $924 billion, with upcoming obligations taking total future obligations above $1 trillion. Caterpillar slumped despite adjusted earnings of $7.20 per share and revenue of $20.68 billion versus $20.65 billion consensus. Eli Lilly raised its full-year sales forecast to $91 billion–$92 billion, and shares rose 8.6% at the New York open; about 500,000 Medicare patients access its obesity medicines through the Bridge program.

Analysis

The key read-through is a widening gap between AI investment and monetization, not simply a broad technology or industrial signal. For Alphabet (GOOG), slower search-ad growth raises the hurdle for returns on committed compute and energy capacity: if AI products do not defend search economics or create new paid usage, fixed commitments can constrain future capital allocation and amplify multiple compression. Those commitments are not equivalent to funded debt, however, and the quarter alone does not establish that AI demand is weakening. Meta and Amazon may benefit if advertisers reallocate budgets, while Microsoft remains exposed to the same question of monetizing large AI infrastructure outlays.

Caterpillar (CAT) is an imperfect AI-infrastructure barometer: its results span end markets beyond data centers, so the reaction may be more about elevated expectations and cyclicality than a confirmed collapse in AI-related orders. Watch order trends and management commentary before extrapolating to suppliers such as Vertiv.

Eli Lilly (LLY) has the clearest near-term fundamental direction, but broader access is valuable only if it converts into sustained, reimbursed treatment and supply can meet demand. Medicare Bridge access is not, by itself, proof of durable coverage economics. Novo Nordisk remains a competitive check. Over 1–3 months, evidence on payer coverage, realized volume and supply matters more than headline access; over 6–18 months, reimbursement and competition determine whether growth supports the premium embedded in the shares. The contrarian risk is that the sharp LLY reaction prices access as recurring demand before that conversion is demonstrated.

Key Decisions for Investors

• GOOG: Avoid chasing the initial decline; consider a staged long only if subsequent results stabilize search-ad growth and show AI investment translating into monetization. Falsifier: another deceleration in search-ad growth alongside rising resource commitments or weaker forward commentary.
• CAT: Do not use the selloff alone to short the AI build-out. Keep exposure light or wait for order/backlog evidence separating data-center demand from broader industrial cycles; reassess if management signals sustained weakness in relevant orders.
• LLY: Favor holding or adding only on confirmation that access expansion produces paid, persistent volume and adequate supply, rather than treating the guidance increase as proof of durable reimbursement. Track realized sales, payer coverage and competitive developments from Novo Nordisk; failure to convert access into revenue would challenge the rally.
• Near-term risk: all three moves can reverse on follow-up guidance and positioning. Avoid a forced cross-sector pair until evidence clarifies whether the market is repricing AI returns broadly or reacting to company-specific execution.